香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 ESPRIT HOLDINGS LIMITED （於百慕達註冊成立之有限公司） 股份代號：00330 截至二零二五年六月三十日止六個月之中期業績公佈 中期業績 3 思捷環球控股有限公司（「本公司」）董事會（「董事會」）公佈本公司及其附屬公司 （「本集團」）截至二零二五年六月三十日止六個月（「本期間」）之未經審核簡明綜合 中期財務資料連同經挑選的附註如下： 1 簡明綜合中期財務資料 簡明綜合損益表 | | | 未經審核 | 未經審核 | | --- | --- | --- | --- | | | | 截至 | 截至 | | | | 二零二五年 | 二零二四年 | | | | 六月三十日 | 六月三十日 | | | 附註 | 止六個月 | 止六個月 | | | | | （經重列） | | | | 千港元 | 千港元 | | 持續經營業務 | | | | | 收入 | 2 | 6,595 | 26,070 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截止2025年6月30日，我們的收入為人民幣326.8百萬元，同比增長了22.2%； 我們的毛利為人民幣21.0百萬元，同比增長了152.1%；毛利率為6.4%，同比增 長3.3百分點；我們的虧損為人民幣174.2百萬元，同比擴大了12.9%，虧損同比 擴大的主要原因是信用減值虧損撥備。 1 Breton Technology Co., Ltd. 博雷頓科技股份公司 （於中華人民共和國成立的股份有限公司） （股份代號：1333） 截至2025年6月30日止六個月 中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明綜合中期 業績，連同截至2024年6月30日止六個月的比較數字。 財務摘要 截至6月30日止六個月 | | 2025年 | 2024年 | | --- | --- | --- | | | 人民幣千元 | 人民幣千元 | | | （未經審核） | （未經審核） | | ...

[Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=1&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The company reported a substantial reduction in loss for the period despite a decrease in revenue, primarily driven by a positive shift in financial asset fair value changes Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (For the six months ended June 30): | Indicator | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 69,577 | 88,516 | -21.4% | | Cost of Sales | (44,383) | (50,664) | -12.4% | | Gross Profit | 25,194 | 37,852 | -33.5% | | Other Income, Gains and Losses, Net | 792 | 2,571 | -69.2% | | Selling and Distribution Costs | (21,760) | (23,920) | -9.0% | | Administrative Expenses | (14,729) | (19,631) | -25.0% | | Gain (Loss) on Fair Value Change of Financial Assets at Fair Value Through Profit or Loss | 8,979 | (12,028) | N/A (Turned from loss to gain) | | Loss Before Income Tax | (9,334) | (22,620) | -58.7% | | Loss for the Period | (9,285) | (24,264) | -61.7% | | Loss for the Period Attributable to Owners of the Company | (9,125) | (24,264) | -62.4% | | Basic and Diluted Loss Per Share (HK Cents) | (0.18) | (0.48) | -62.5% | [Condensed Consolidated Statement of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) The company's financial position shows a slight increase in total assets and equity, with improved net current assets and reduced current liabilities Condensed Consolidated Statement of Financial Position (As at June 30/December 31): | Indicator | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current Assets | 208,731 | 205,545 | +1.5% | | Current Assets | 304,340 | 312,048 | -2.5% | | Current Liabilities | 74,177 | 84,028 | -11.7% | | Net Current Assets | 230,163 | 228,020 | +0.9% | | Total Assets Less Current Liabilities | 438,894 | 433,565 | +1.2% | | Non-current Liabilities | 7,981 | 7,074 | +12.8% | | Net Assets | 430,913 | 426,491 | +1.0% | | Total Equity | 430,913 | 426,491 | +1.0% | [Notes to the Condensed Consolidated Interim Financial Statements](index=5&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section details the preparation basis, principal accounting policies, and the impact of revised Hong Kong Financial Reporting Standards on the interim financial statements - The financial statements are prepared in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" and applicable disclosure provisions of the HKEX Listing Rules[6](index=6&type=chunk)[7](index=7&type=chunk) - The revised Hong Kong Financial Reporting Standards were first applied in this interim period, with no significant impact on financial position or performance[8](index=8&type=chunk) [1. Basis of Preparation and Principal Accounting Policies](index=5&type=section&id=1.%20Basis%20of%20Preparation%20and%20Principal%20Accounting%20Policies) This chapter explains that the condensed consolidated interim financial statements are prepared under HKAS 34 and HKEX Listing Rules, using a historical cost basis consistent with prior annual financial statements [1.1 Basis of Preparation](index=5&type=section&id=1.1%20Basis%20of%20Preparation) The condensed consolidated interim financial statements are prepared in accordance with HKAS 34 "Interim Financial Reporting" and applicable disclosure provisions of the HKEX Listing Rules, and should be read in conjunction with the annual financial statements - The financial statements are prepared in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" and applicable disclosure provisions of the HKEX Listing Rules[6](index=6&type=chunk) [1.2 Principal Accounting Policies](index=5&type=section&id=1.2%20Principal%20Accounting%20Policies) The unaudited condensed consolidated interim financial statements are prepared on a historical cost basis, with accounting policies and methods of computation consistent with the prior year's annual consolidated financial statements, except for the application of revised HKFRS - The financial statements are prepared on a historical cost basis, with certain financial instruments measured at fair value[7](index=7&type=chunk) - Except for the application of revised Hong Kong Financial Reporting Standards, accounting policies are consistent with the prior year's consolidated financial statements[7](index=7&type=chunk) [2. Application of Revised Hong Kong Financial Reporting Standards](index=5&type=section&id=2.%20Application%20of%20Revised%20Hong%20Kong%20Financial%20Reporting%20Standards) During this interim period, the Group first applied revised HKFRS (HKAS 21 (Amendment) Lack of Exchangeability), which had no significant impact on the financial position, performance, or disclosures for current and prior periods - Hong Kong Accounting Standard 21 (Amendment) "Lack of Exchangeability" was first applied in this interim period[8](index=8&type=chunk) - The application of revised standards had no significant impact on the financial position, performance, or disclosures for the current and prior periods[8](index=8&type=chunk) [3. Revenue and Segment Information](index=6&type=section&id=3.%20Revenue%20and%20Segment%20Information) The Group operates in two segments: dental business and healthcare business, with total revenue of HK$69,577 thousand in H1 2025, where the dental business contributed HK$66,433 thousand and the healthcare business HK$3,144 thousand, with the dental business facing losses while the healthcare business achieved profitability - The Group's operations are divided into two segments: dental business and healthcare business[9](index=9&type=chunk) Segment Revenue (For the six months ended June 30): | Segment | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Dental Business | 66,433 | 85,888 | -22.6% | | Healthcare Business | 3,144 | 2,628 | +19.6% | | **Total Revenue** | **69,577** | **88,516** | **-21.4%** | Segment Operating (Loss) Profit (For the six months ended June 30): | Segment | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Dental Business | (16,658) | (2,986) | | Healthcare Business | 757 | (1,252) | | **Total Segment Operating (Loss) Profit** | **(15,901)** | **(4,238)** | [3.1 Segment Revenue and Results](index=6&type=section&id=3.1%20Segment%20Revenue%20and%20Results) In H1 2025, dental business revenue decreased by 22.6% year-on-year to HK$66,433 thousand, recording an operating loss of HK$16,658 thousand, while healthcare business revenue increased by 19.6% year-on-year to HK$3,144 thousand, achieving an operating profit of HK$757 thousand, leading to an overall segment operating loss of HK$15,901 thousand Segment Revenue and Operating Results (For the six months ended June 30): | Indicator | Dental Business (HK$ Thousand) | Healthcare Business (HK$ Thousand) | Total (HK$ Thousand) | | :--- | :--- | :--- | :--- | | **2025 Revenue** | 66,433 | 3,144 | 69,577 | | **2025 Segment Operating (Loss) Profit** | (16,658) | 757 | (15,901) | | **2024 Revenue** | 85,888 | 2,628 | 88,516 | | **2024 Segment Operating Loss** | (2,986) | (1,252) | (4,238) | - Dental business revenue decreased, and operating loss expanded; healthcare business revenue grew, achieving operating profit[10](index=10&type=chunk)[11](index=11&type=chunk) [3.2 Segment Assets and Liabilities](index=8&type=section&id=3.2%20Segment%20Assets%20and%20Liabilities) As of June 30, 2025, the Group's total reportable segment assets were HK$511,923 thousand, with dental business assets at HK$271,757 thousand and healthcare business assets at HK$240,166 thousand, and total liabilities were HK$82,158 thousand, showing a decrease in both total assets and liabilities compared to December 31, 2024 Segment Assets and Liabilities (As at June 30/December 31): | Indicator | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Reportable Segment Assets | 511,923 | 515,802 | | Total Assets | 513,071 | 517,593 | | Reportable Segment Liabilities | (66,441) | (74,695) | | Total Liabilities | (82,158) | (91,102) | [3.3 Geographical Information](index=9&type=section&id=3.3%20Geographical%20Information) The Group's operations are primarily located in Hong Kong and Mainland China (excluding Hong Kong), with over 90% of external customer revenue originating from Mainland China (excluding Hong Kong), and total non-current assets as of June 30, 2025, were HK$46,502 thousand, with Mainland China (excluding Hong Kong) accounting for HK$24,106 thousand - Over **90%** of external customer revenue is from Mainland China (excluding Hong Kong)[13](index=13&type=chunk) Non-current Assets by Geographical Location: | Region | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Mainland China (excluding Hong Kong) | 24,106 | 22,679 | | Other | 22,396 | 22,605 | | **Total** | **46,502** | **45,284** | [3.4 Information About Major Customers](index=9&type=section&id=3.4%20Information%20About%20Major%20Customers) The Group has no individual customer whose revenue accounts for more than 10% of total revenue - No individual customer's revenue accounts for more than **10%** of the Group's total revenue[16](index=16&type=chunk) [4. Loss Before Income Tax](index=10&type=section&id=4.%20Loss%20Before%20Income%20Tax) The loss before income tax for H1 2025 was HK$9,334 thousand, a significant reduction from HK$22,620 thousand in the same period last year, primarily due to a shift from loss to gain in fair value changes of financial assets at fair value through profit or loss, and reduced depreciation, amortization, lease expenses, and R&D expenses Loss Before Income Tax Components (For the six months ended June 30): | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Amortisation of Intangible Assets | 347 | 343 | | Depreciation of Property, Plant and Equipment | 3,289 | 4,056 | | Depreciation of Right-of-use Assets | 2,773 | 3,322 | | Short-term Lease Expenses | 877 | 1,646 | | Research and Development Expenses | 7,779 | 8,584 | | Finance Costs on Lease Liabilities | 228 | 409 | | Bank Interest Income | (746) | (1,090) | | Dividend Income | (201) | (666) | | Net Exchange Gains | 485 | (153) | - Loss before income tax significantly decreased from **HK$22,620 thousand** in 2024 to **HK$9,334 thousand** in 2025[2](index=2&type=chunk) [5. Income Tax Credit (Expense)](index=11&type=section&id=5.%20Income%20Tax%20Credit%20%28Expense%29) The income tax credit for H1 2025 was HK$49 thousand, compared to an expense of HK$1,644 thousand in the prior year, with no taxable profits in Hong Kong and overseas jurisdictions, and a 15% preferential tax rate for a PRC subsidiary due to its high-tech enterprise qualification and R&D super deduction policy Income Tax Credit (Expense) (For the six months ended June 30): | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Current Tax | – | 1,558 | | Deferred Tax (Credit) Expense | (49) | 86 | | **Total** | **(49)** | **1,644** | - Hong Kong and overseas jurisdictions had no taxable profits, thus no Hong Kong profits tax provision was made[19](index=19&type=chunk)[20](index=20&type=chunk) - A PRC subsidiary enjoys a **15%** preferential tax rate due to its high-tech enterprise qualification and can apply for a **175%** super deduction allowance for R&D expenses[21](index=21&type=chunk) [Overseas Income Tax](index=11&type=section&id=Overseas%20Income%20Tax) The Group is not subject to any income tax in the jurisdictions of Bermuda and the British Virgin Islands - The Group is not subject to any income tax in Bermuda and the British Virgin Islands[19](index=19&type=chunk) [Hong Kong Profits Tax](index=11&type=section&id=Hong%20Kong%20Profits%20Tax) No provision for Hong Kong profits tax was made as the Group had no assessable profits for the six months ended June 30, 2025, and 2024 - The Group had no assessable profits in H1 2025 and 2024, thus no provision for Hong Kong profits tax was made[20](index=20&type=chunk) [PRC Enterprise Income Tax](index=11&type=section&id=PRC%20Enterprise%20Income%20Tax) PRC subsidiaries are subject to a 25% enterprise income tax rate, but one subsidiary, recognized as a "High and New Technology Enterprise," qualifies for a 15% preferential tax rate for three tax years from 2024 to 2026 and can apply for a 175% super deduction allowance for R&D expenses - PRC subsidiaries are subject to a **25%** enterprise income tax rate, but one high-tech enterprise enjoys a **15%** preferential tax rate[21](index=21&type=chunk) - Qualified enterprises can apply for a **175%** super deduction allowance for R&D expenses[21](index=21&type=chunk) [6. Dividends](index=12&type=section&id=6.%20Dividends) The company did not pay, declare, or propose any dividends for the six months ended June 30, 2025, and 2024 - For the six months ended June 30, 2025, and 2024, the company neither paid, declared, nor proposed any dividends[22](index=22&type=chunk) [7. Loss Per Share](index=12&type=section&id=7.%20Loss%20Per%20Share) The basic and diluted loss per share attributable to owners of the company for H1 2025 was 0.18 HK Cents, a significant reduction from 0.48 HK Cents in H1 2024, with diluted loss per share being the same as basic loss per share due to the exercise price of share options being higher than the average market price of shares Loss Per Share (For the six months ended June 30): | Indicator | 2025 (HK Cents) | 2024 (HK Cents) | | :--- | :--- | :--- | | Basic and Diluted Loss Per Share | (0.18) | (0.48) | - The exercise price of share options was higher than the average market price of shares, thus diluted loss per share was the same as basic loss per share[24](index=24&type=chunk)[25](index=25&type=chunk) [8. Financial Assets at Fair Value Through Profit or Loss](index=13&type=section&id=8.%20Financial%20Assets%20at%20Fair%20Value%20Through%20Profit%20or%20Loss) As of June 30, 2025, total financial assets at fair value through profit or loss amounted to HK$162,229 thousand, a slight increase from December 31, 2024, primarily comprising limited partnership interests in Zhuhai Partnership and Haoyi Partnership, with a fair value change gain of HK$8,979 thousand recorded for the period Financial Assets at Fair Value Through Profit or Loss (As at June 30/December 31): | Item | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Zhuhai Partnership | 119,451 | 116,919 | | Haoyi Partnership | 42,778 | 43,342 | | **Total** | **162,229** | **160,261** | - A fair value change gain of **HK$8,979 thousand** was recorded for financial assets at fair value through profit or loss in the current period, compared to a loss of HK$9,772 thousand in the prior period[32](index=32&type=chunk) - The company's directors believe there is no actual control or significant influence over the two limited partnership entities, hence they are measured at fair value through profit or loss[26](index=26&type=chunk) [(a) Zhuhai Partnership](index=13&type=section&id=%28a%29%20Zhuhai%20Partnership) The Group holds a 5.51% equity interest in Zhuhai Partnership, which primarily invests in equity and equity-related securities in information technology and high-quality healthcare industries, and exercises financial and operational control over Shenzhen Dayi Zhen Technology Co Ltd (the equity holder of Zhuhai Partnership) through contractual arrangements (VIE agreements), consolidating its financial information into the consolidated financial statements - The Group holds a **5.51%** equity interest in Zhuhai Partnership, primarily investing in information technology and high-quality healthcare industries[27](index=27&type=chunk) - Through cooperation agreements and VIE agreements with Shenzhen Yingdu and Shenzhen Dayi Zhen Technology Co Ltd, the Group exercises effective control over Shenzhen Dayi Zhen and consolidates its financial information into the consolidated financial statements[28](index=28&type=chunk)[30](index=30&type=chunk) - Legal counsel believes the contractual arrangements comply with PRC laws and regulations, are valid, binding, and legally enforceable[29](index=29&type=chunk) [(b) Haoyi Partnership](index=15&type=section&id=%28b%29%20Haoyi%20Partnership) The Group holds a 99.9% limited partnership interest in Haoyi Partnership, which focuses on China's healthcare business, and after selling part of its equity in 2023, the Group lost control, joint control, or significant influence over Haoyi Partnership, thus classifying it as a financial asset at fair value through profit or loss - The Group holds a **99.9%** limited partnership interest in Haoyi Partnership, which focuses on China's healthcare business[31](index=31&type=chunk) - After selling part of its equity in 2023, the Group lost control over Haoyi Partnership, classifying it as a financial asset at fair value through profit or loss[31](index=31&type=chunk) [9. Trade and Other Receivables](index=16&type=section&id=9.%20Trade%20and%20Other%20Receivables) As of June 30, 2025, total trade and other receivables amounted to HK$140,842 thousand, a decrease from HK$148,177 thousand as of December 31, 2024, with a net reversal of impairment allowance for trade receivables of HK$197 thousand Trade and Other Receivables (As at June 30/December 31): | Item | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Trade Receivables (net of impairment) | 98,178 | 111,201 | | Other Receivables related to Land Use Rights Acquisition | 21,935 | 21,202 | | Other Receivables, Prepayments and Deposits (net of impairment) | 42,664 | 36,976 | | **Total** | **140,842** | **148,177** | - Net reversal of impairment loss for trade receivables was **HK$197 thousand**[2](index=2&type=chunk) [(a) Trade Receivables](index=16&type=section&id=%28a%29%20Trade%20Receivables) As of June 30, 2025, trade receivables (net of impairment) were HK$98,178 thousand, a decrease from HK$111,201 thousand as of December 31, 2024, with an increased proportion of receivables aged 91 to 180 days and over one year Trade Receivables Ageing Analysis (As at June 30/December 31): | Ageing | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | 0 to 90 days | 23,604 | 57,282 | | 91 to 180 days | 42,358 | 27,105 | | 181 to 365 days | 19,706 | 20,003 | | Over one year | 12,510 | 6,811 | | **Total** | **98,178** | **111,201** | - The average credit period for trade receivables is **30 to 90 days**, with some good customers extending up to **360 days**[34](index=34&type=chunk) [(b) Other Receivables, Prepayments and Deposits](index=17&type=section&id=%28b%29%20Other%20Receivables%2C%20Prepayments%20and%20Deposits) As of June 30, 2025, other receivables related to the acquisition of land use rights amounted to HK$21,935 thousand, while a deposit of HK$20,000 thousand previously paid by the Group for a rural revitalization project was fully impaired in 2024 due to the termination of the original cooperation agreement and non-payment by the counterparty - As of June 30, 2025, other receivables related to the acquisition of land use rights amounted to **HK$21,935 thousand**[33](index=33&type=chunk) - In 2024, a **HK$20,000 thousand** deposit for land use rights was fully impaired due to the termination of the original cooperation agreement and non-payment by the counterparty[36](index=36&type=chunk) [(c) Movement in Impairment of Other Receivables](index=18&type=section&id=%28c%29%20Movement%20in%20Impairment%20of%20Other%20Receivables) As of June 30, 2025, the impairment allowance for other receivables increased to HK$29,994 thousand, primarily due to an exchange adjustment increase of HK$1,002 thousand Movement in Impairment of Other Receivables (As at June 30/December 31): | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | At January 1 | 28,992 | 7,817 | | Recognized during the year | – | 21,893 | | Exchange adjustment | 1,002 | (718) | | **At June 30/December 31** | **29,994** | **28,992** | [(d) Other](index=18&type=section&id=%28d%29%20Other) The directors believe there is no material difference between the fair value and carrying amount of trade and other receivables expected to be realized within one year, as these balances are due in the short term - The fair value of trade and other receivables has no material difference from their carrying amount, as all balances are due in the short term[37](index=37&type=chunk) [10. Amounts Due From/To Fellow Subsidiaries/Ultimate Holding Company](index=18&type=section&id=10.%20Amounts%20Due%20From%2FTo%20Fellow%20Subsidiaries%2FUltimate%20Holding%20Company) These amounts are unsecured, interest-free, and repayable on demand, and the directors believe there has been no significant increase in credit risk or default rates for amounts due from fellow subsidiaries - Amounts due from/to fellow subsidiaries/ultimate holding company are unsecured, interest-free, and repayable on demand[38](index=38&type=chunk) - The directors believe there has been no significant increase in credit risk or default rates for amounts due from fellow subsidiaries[38](index=38&type=chunk) [11. Trade and Other Payables](index=18&type=section&id=11.%20Trade%20and%20Other%20Payables) As of June 30, 2025, total trade and other payables amounted to HK$55,122 thousand, a decrease from HK$64,773 thousand as of December 31, 2024, with an increase in trade payables and a decrease in advances received and other payables Trade and Other Payables (As at June 30/December 31): | Item | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Trade Payables | 9,495 | 5,552 | | Advances Received | 18,326 | 25,058 | | Other Payables | 13,763 | 20,688 | | Accrued Charges | 9,619 | 10,485 | | Contract Liabilities | 3,919 | 2,990 | | **Total** | **55,122** | **64,773** | [(a) Trade Payables](index=19&type=section&id=%28a%29%20Trade%20Payables) As of June 30, 2025, trade payables were HK$9,495 thousand, an increase from HK$5,552 thousand as of December 31, 2024, with an average credit period of 90 days Trade Payables Ageing Analysis (As at June 30/December 31): | Ageing | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | 0 to 90 days | 7,741 | 5,179 | | 91 to 180 days | 1,389 | 295 | | Over 180 days | 365 | 78 | | **Total** | **9,495** | **5,552** | - The average credit period for purchases of goods is **90 days**[40](index=40&type=chunk) [(b) Other Payables](index=19&type=section&id=%28b%29%20Other%20Payables) Other payables primarily include PRC Value Added Tax and other taxes payable - Other payables primarily include PRC Value Added Tax and other taxes payable[40](index=40&type=chunk) [(c) Accrued Charges](index=19&type=section&id=%28c%29%20Accrued%20Charges) Accrued charges primarily include staff salaries and allowances, contributions to defined contribution retirement schemes, and consulting fees for dental and healthcare projects - Accrued charges primarily include staff salaries, retirement scheme contributions, and consulting fees for dental and healthcare projects[40](index=40&type=chunk) [(d) Contract Liabilities](index=19&type=section&id=%28d%29%20Contract%20Liabilities) Contract liabilities represent advances received for medical services under the healthcare business segment, amounting to HK$3,919 thousand as of June 30, 2025, an increase from December 31, 2024 - Contract liabilities represent advances received for medical services under the healthcare business segment[40](index=40&type=chunk) Movement in Contract Liabilities (As at June 30/December 31): | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | At January 1 | 2,990 | 2,536 | | Additions | 4,073 | 6,772 | | Revenue recognized during the year | (3,144) | (6,318) | | **At June 30/December 31** | **3,919** | **2,990** | [(e) Other](index=20&type=section&id=%28e%29%20Other) The directors consider that all amounts are short-term, and therefore the carrying amounts of the Group's trade and other payables are considered to approximate their fair values - The carrying amounts of trade and other payables are considered to approximate their fair values, as all amounts are short-term[41](index=41&type=chunk) [Management Discussion and Analysis](index=21&type=section&id=Management%20Discussion%20and%20Analysis) The Group's H1 2025 revenue decreased by 21.4%, but the loss attributable to owners of the company significantly narrowed by 62.4%, primarily due to a positive shift in the fair value of financial assets - The Group's H1 2025 revenue decreased by **21.4%**, but the loss attributable to owners of the company significantly narrowed by **62.4%**[42](index=42&type=chunk) - Dental business revenue declined due to centralized procurement policies, while healthcare business revenue increased by **15%** year-on-year[44](index=44&type=chunk)[46](index=46&type=chunk) - The positive shift in fair value changes of financial assets at fair value through profit or loss was a primary reason for the narrowed loss[42](index=42&type=chunk)[51](index=51&type=chunk) [Financial Highlights](index=21&type=section&id=Financial%20Highlights) In H1 2025, the Group's revenue was approximately HK$69,600 thousand, a 21.4% year-on-year decrease, with gross profit margin falling to 36.2%, while the loss attributable to owners of the company significantly narrowed to approximately HK$9,100 thousand (HK$24,300 thousand in the prior year), and basic and diluted loss per share was 0.18 HK Cents Financial Highlights (For the six months ended June 30): | Indicator | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 69,600 | 88,500 | -21.4% | | Gross Margin | 36.2% | 42.8% | -6.6 percentage points | | Loss Attributable to Owners of the Company | (9,100) | (24,300) | -62.5% | | Basic and Diluted Loss Per Share (HK Cents) | (0.18) | (0.48) | -62.5% | [Interim Dividend](index=21&type=section&id=Interim%20Dividend) The Board of Directors does not recommend the payment of an interim dividend for the current period, consistent with the prior year - The Board of Directors does not recommend the payment of an interim dividend for the current period[43](index=43&type=chunk) [Business Review](index=21&type=section&id=Business%20Review) The Group primarily operates dental and healthcare businesses, with dental business revenue decreasing by 22.6% due to centralized procurement policies, but continuing to invest in R&D and market expansion, while healthcare business revenue increased by 15% year-on-year and successfully renewed its medical insurance designated institution qualification - The Group primarily engages in dental business (sales and production of prosthetics) and healthcare business (sports rehabilitation services)[9](index=9&type=chunk)[44](index=44&type=chunk)[46](index=46&type=chunk) - Dental business revenue decreased, but the Group continues to invest in R&D and plans to establish regional manufacturing centers in Shanghai and Chengdu[44](index=44&type=chunk)[45](index=45&type=chunk) - Healthcare business revenue increased by **15%** year-on-year and successfully renewed its Shenzhen medical insurance designated institution qualification[46](index=46&type=chunk) [Dental Business](index=21&type=section&id=Dental%20Business) The dental business, primarily involving the sale and production of prosthetics, generated approximately HK$66,400 thousand in H1 2025, a year-on-year decrease of approximately HK$19,500 thousand, with the Group continuing to invest in R&D (approximately HK$7,800 thousand) and planning to establish regional manufacturing centers in Shanghai and Chengdu to reduce logistics costs, and despite the impact of centralized procurement policies and industry competition, the implant business has entered more chain dental institutions - Dental business revenue was approximately **HK$66,400 thousand**, a decrease of approximately **HK$19,500 thousand** compared to the prior year[44](index=44&type=chunk) - R&D expenses were approximately **HK$7,800 thousand**, reflecting management's commitment to future technology investment[45](index=45&type=chunk) - Plans include establishing regional manufacturing centers in Shanghai and Chengdu to reduce logistics costs and expanding the Sino-US implant R&D center team[44](index=44&type=chunk)[45](index=45&type=chunk) [Healthcare Business](index=22&type=section&id=Healthcare%20Business) Hejia Rehabilitation Clinic successfully met the Shenzhen Medical Insurance Bureau's performance assessment, smoothly renewing its medical insurance designated institution qualification, expanded its team in H1 2025, increased operating revenue by 15% year-on-year, and became Shenzhen's most widely distributed medical-grade sports rehabilitation center, enhancing its industry influence - Hejia Rehabilitation Clinic successfully renewed its Shenzhen medical insurance designated institution qualification, with operating revenue increasing by **15%** year-on-year[46](index=46&type=chunk) - It has become Shenzhen's most widely distributed medical-grade sports rehabilitation center and was invited to be a理事单位 of the National Sports Rehabilitation Industry Alliance, enhancing its industry influence[64](index=64&type=chunk) [Operating Results and Financial Review](index=23&type=section&id=Operating%20Results%20and%20Financial%20Review) This section provides a detailed analysis of the Group's revenue, gross profit, financial assets, cash flow, capital expenditure, contingent liabilities, and treasury policy, noting that revenue decline was primarily due to China's government centralized procurement policies, which also led to a lower gross profit margin, while fair value changes of financial assets shifted from loss to gain, bank balances remained robust, and capital expenditure increased - Revenue decreased by **21.4%** to **HK$69,600 thousand**, primarily due to reduced average selling prices of dental products caused by China's government centralized procurement policies[47](index=47&type=chunk) - Gross profit decreased by **33.5%** to **HK$25,200 thousand**, with gross profit margin falling to **36.2%**, mainly due to lower average selling prices during the period[48](index=48&type=chunk) - Fair value changes of financial assets at fair value through profit or loss shifted from loss to gain, accounting for approximately **31.6%** of total assets[51](index=51&type=chunk) [Revenue](index=23&type=section&id=Revenue) Revenue for the period was approximately HK$69,600 thousand, a decrease of approximately 21.4% compared to the prior year, primarily due to the continued adverse impact of China's government centralized procurement price policies on the average selling prices of dental products Revenue (For the six months ended June 30): | Indicator | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Revenue | 69,600 | 88,500 | - Revenue decreased primarily due to reduced average selling prices of dental products caused by China's government centralized procurement price policies[47](index=47&type=chunk) [Gross Profit and Gross Margin](index=23&type=section&id=Gross%20Profit%20and%20Gross%20Margin) Gross profit for the period was approximately HK$25,200 thousand, a decrease of approximately 33.5% compared to the prior year, with gross profit margin at approximately 36.2%, a 6.6 percentage point decrease from the prior year, mainly due to lower average selling prices Gross Profit and Gross Margin (For the six months ended June 30): | Indicator | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Gross Profit | 25,200 | 37,900 | | Gross Margin | 36.2% | 42.8% | - The decrease in gross profit margin was primarily due to lower average selling prices during the period[48](index=48&type=chunk) [Financial Assets at Fair Value Through Profit or Loss](index=23&type=section&id=Financial%20Assets%20at%20Fair%20Value%20Through%20Profit%20or%20Loss) As of June 30, 2025, the fair value of financial assets at fair value through profit or loss was approximately HK$162,200 thousand, an increase of approximately 1.2% from December 31, 2024, mainly due to the increased valuation of related equity and equity-related securities invested by Zhuhai Partnership, with a fair value gain of approximately HK$9,000 thousand recorded for the period Financial Assets at Fair Value Through Profit or Loss (As at June 30): | Investee | 2025 Fair Value (HK$ Million) | 2025 Fair Value Gain/(Loss) (HK$ Million) | | :--- | :--- | :--- | | Zhuhai Jinyiming Equity Investment Fund Partnership | 119.4 | 11.0 | | Haoyi Kangyang Services (Shenzhen) Partnership | 42.8 | (2.0) | | **Total** | **162.2** | **9.0** | - Financial assets increased by approximately **1.2%**, primarily due to the increased valuation of investments by Zhuhai Partnership[51](index=51&type=chunk) - Management will review the performance of partnership investments quarterly to determine the investment approach[52](index=52&type=chunk) [Zhuhai Partnership](index=23&type=section&id=Zhuhai%20Partnership) The Group holds a 5.51% limited partnership interest in Zhuhai Partnership through contractual arrangements, with an investment cost of RMB180,000,000, and this entity specializes in equity and equity-related securities in information technology, high-quality medical, and healthcare industries - The Group holds a **5.51%** limited partnership interest in Zhuhai Partnership through contractual arrangements, with an investment cost of **RMB180,000,000**[49](index=49&type=chunk) - Zhuhai Partnership's investment portfolio focuses on information technology, high-quality medical, and healthcare industries[49](index=49&type=chunk) [Haoyi Partnership](index=24&type=section&id=Haoyi%20Partnership) After selling part of its equity in 2023, the Group lost control over Haoyi Partnership, now holding a 99.9% limited partnership interest and classifying it as a financial asset at fair value through profit or loss, with Haoyi Partnership investing in the Zhuhai Shilianjiang project through Guanghao and its subsidiaries - The Group holds a **99.9%** limited partnership interest in Haoyi Partnership, which has been classified as a financial asset at fair value through profit or loss[50](index=50&type=chunk) - Haoyi Partnership invests in the Zhuhai Shilianjiang project through Guanghao and its subsidiaries[50](index=50&type=chunk) [Material Investments, Material Acquisitions and Disposals](index=25&type=section&id=Material%20Investments%2C%20Material%20Acquisitions%20and%20Disposals) Except as disclosed in this announcement, the Group made no other material investments or material acquisitions or disposals of subsidiaries, associates, or joint ventures during the period - The Group had no other material investments, acquisitions, or disposals during the period[53](index=53&type=chunk) [Bank Balances and Cash](index=25&type=section&id=Bank%20Balances%20and%20Cash) As of June 30, 2025, the Group's bank balances and cash were approximately HK$146,900 thousand, a slight decrease from December 31, 2024, but still maintaining a robust cash level Bank Balances and Cash (As at June 30/December 31): | Indicator | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Bank Balances and Cash | 146,900 | 149,600 | - The Group maintained a robust cash level during the review period[54](index=54&type=chunk) [Capital Expenditure and Capital Commitments](index=25&type=section&id=Capital%20Expenditure%20and%20Capital%20Commitments) During the period, the Group invested approximately HK$9,300 thousand, primarily in right-of-use assets and production equipment, a significant increase from the prior year, and as of June 30, 2025, the Group had no capital expenditure commitments Capital Expenditure (For the six months ended June 30): | Indicator | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | | :--- | :--- | :--- | | Capital Expenditure | 9,300 | 2,100 | - Capital expenditure was primarily used for right-of-use assets and production equipment[55](index=55&type=chunk) - As of June 30, 2025, the Group had no capital expenditure commitments[55](index=55&type=chunk) [Contingent Liabilities](index=25&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no contingent liabilities - As of June 30, 2025, the Group had no contingent liabilities[56](index=56&type=chunk) [Pledge of the Group's Assets](index=25&type=section&id=Pledge%20of%20the%20Group%27s%20Assets) As of June 30, 2025, none of the Group's assets were pledged to secure bank financing - As of June 30, 2025, none of the Group's assets were pledged to obtain bank financing[57](index=57&type=chunk) [Treasury Policy](index=25&type=section&id=Treasury%20Policy) The Group's sales and purchases are primarily denominated in RMB and USD, with cash mainly held in USD, RMB, and HKD, and while directors currently anticipate no significant exchange rate fluctuation risks and have not entered into hedging financial instruments, they will closely monitor foreign exchange and interest rate risks - Group sales and purchases are primarily denominated in **RMB** and **USD**, with cash mainly held in **USD**, **RMB**, and **HKD**[58](index=58&type=chunk) - Directors currently anticipate no significant exchange rate fluctuation risks and have not entered into hedging financial instruments, but will closely monitor foreign exchange and interest rate risks[58](index=58&type=chunk) [Liquidity, Capital Structure and Financial Resources](index=26&type=section&id=Liquidity%2C%20Capital%20Structure%20and%20Financial%20Resources) As of June 30, 2025, equity attributable to owners of the company was approximately HK$435,900 thousand, with net current assets of approximately HK$230,200 thousand, and liquidity and quick ratios of 4.10 and 3.89 respectively, both showing improvement and indicating ample liquidity, with no net debt, and management believes there are sufficient resources to meet obligations and fund future operational expansion Liquidity Indicators (As at June 30/December 31): | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Equity Attributable to Owners of the Company (HK$ Thousand) | 435,900 | 431,200 | | Net Current Assets (HK$ Thousand) | 230,200 | 228,000 | | Current Ratio | 4.10 | 3.71 | | Quick Ratio | 3.89 | 3.55 | - The Group has no net debt, and thus no gearing ratio is calculated[59](index=59&type=chunk) - Management believes the Group has ample resources to settle outstanding debts and fund daily operations and future expansion[60](index=60&type=chunk) [Outlook](index=26&type=section&id=Outlook) The Group will continue to focus on its core dental and healthcare businesses, aiming to enhance shareholder value by expanding sales networks, improving production capacity, developing high-end products, and seeking investment cooperation, thereby building the "Mega" and "Basic Dental" brands and forming an ecological cycle combining upstream and downstream oral care with medical and elderly care - The Group's business strategy is to further enhance shareholder value through expanded operations[61](index=61&type=chunk) - The Group aims to build the "Mega" and "Basic Dental" brands to become a high-end prosthetic consumables supplier[61](index=61&type=chunk) - The Group actively explores upstream and downstream medical device systems for oral care, and integrated medical and elderly care service systems, to form an ecological cycle[61](index=61&type=chunk) [Dental Business](index=27&type=section&id=Dental%20Business) The Group anticipates continued rapid growth in China's dental market and has formulated growth strategies including expanding domestic and international sales networks, enhancing production capacity, developing high-end new dental products, actively participating in exhibitions and public hospital tenders, and seeking investment and cooperation opportunities in high-tech dental-related fields - China's dental market is expected to maintain rapid growth, with several times its current development potential[62](index=62&type=chunk) - Growth strategies include expanding domestic and international sales networks, enhancing production capacity, developing high-end new dental products, and actively participating in exhibitions and public hospital tenders[62](index=62&type=chunk) - Continuous improvement of Basic Dental production processes, addition of automated equipment, and expansion of distribution networks are expected to lead to significant growth in the implant business[63](index=63&type=chunk) [Healthcare Business](index=27&type=section&id=Healthcare%20Business) With tightening approval and consumption management standards for Shenzhen medical insurance designated institutions, Hejia Rehabilitation Clinic, as a medical insurance designated unit, has gained more patient trust and has become Shenzhen's most widely distributed medical-grade sports rehabilitation center, further enhancing its professional influence in the industry - Hejia Rehabilitation Clinic, as a Shenzhen medical insurance designated unit, has gained more patient trust[64](index=64&type=chunk) - It has become Shenzhen's most widely distributed medical-grade sports rehabilitation center and was invited to be a理事单位 of the National Sports Rehabilitation Industry Alliance, enhancing its professional industry influence[64](index=64&type=chunk) [Significant Events After the Reporting Period](index=28&type=section&id=Significant%20Events%20After%20the%20Reporting%20Period) No significant events affecting the company have occurred since June 30, 2025, up to the date of this announcement - No significant events affecting the company have occurred after the reporting period[65](index=65&type=chunk) [Employees and Remuneration Policy](index=28&type=section&id=Employees%20and%20Remuneration%20Policy) As of June 30, 2025, the Group had approximately 917 employees, with a remuneration policy based on Group and employee performance, providing benefits such as social insurance and pensions, and adopting a share option scheme for long-term incentives Employee Count: | Date | Employee Count | | :--- | :--- | | June 30, 2025 | 917 | | December 31, 2024 | 861 | - The remuneration policy is based on Group and employee performance, providing social insurance, pension, and other benefits, and adopting a share option scheme for long-term incentives[66](index=66&type=chunk) [Directors' Compliance with the Model Code for Securities Transactions](index=28&type=section&id=Directors%27%20Compliance%20with%20the%20Model%20Code%20for%20Securities%20Transactions) The company has adopted the Model Code set out in Appendix C3 of the Listing Rules and established written guidelines for employees, with all directors confirming compliance with the Model Code during the period, and no instances of non-compliance by employees were found - The company has adopted the Model Code set out in Appendix C3 of the Listing Rules and established written guidelines for employees that are no less exacting than the Model Code[67](index=67&type=chunk) - All directors have confirmed compliance with the Model Code, and no instances of non-compliance by employees were found[67](index=67&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=28&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20the%20Company%27s%20Listed%20Securities) During the period, neither the company nor its subsidiaries purchased, sold, or redeemed any of the company's listed securities - Neither the company nor its subsidiaries purchased, sold, or redeemed any of the company's listed securities during the period[68](index=68&type=chunk) [Compliance with the Corporate Governance Code](index=28&type=section&id=Compliance%20with%20the%20Corporate%20Governance%20Code) For the six months ended June 30, 2025, the company has complied with all relevant code provisions of the Corporate Governance Code set out in Part 2 of Appendix C1 of the Listing Rules - The company has complied with all relevant code provisions of the Corporate Governance Code set out in Part 2 of Appendix C1 of the Listing Rules[69](index=69&type=chunk) [Review of Financial Information](index=29&type=section&id=Review%20of%20Financial%20Information) The company's audit committee, comprising three independent non-executive directors, has reviewed the Group's unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025 - The audit committee, comprising three independent non-executive directors, has reviewed the Group's unaudited condensed consolidated interim financial statements[70](index=70&type=chunk) [Publication of 2025 Interim Results and Interim Report](index=29&type=section&id=Publication%20of%202025%20Interim%20Results%20and%20Interim%20Report) The interim results announcement has been published on the websites of Hong Kong Exchanges and Clearing Limited and the company, and the interim report will be dispatched to shareholders and published on the aforementioned websites in due course as required by the Listing Rules - The interim results announcement has been published on the Hong Kong Exchange and company websites[71](index=71&type=chunk) - The interim report will be dispatched to shareholders and published on the websites in due course as required by the Listing Rules[71](index=71&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 SINOTRUK (HONG KONG) LIMITED 中 國 重 汽（ 香 港 ）有 限 公 司 （於香港註冊成立的有限公司） （股份代號：03808） 截 至 2025 年 6 月 30 日 止 6 個月中期業績公佈 業績 董事會欣然公佈本集團截至2025年6月30日止6個月之未經審核中期業績及與上年 同期之比較數字如下： 綜合損益表 截至2025年6月30日止6個月－未經審核 （除另外說明外，所有金額以人民幣千元計） | | | 截至6月30日止6個月 | | | --- | --- | --- | --- | | | 附註 | 2025年 | 2024年 | | 收入 | 4 | 50,878,062 | 48,823,239 | | 銷售成本 | | (43,216,438) | (41,664,507) | | 毛利 | | 7,661,624 | 7,158,732 | | 其他收入及利 ...

由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣 之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通 量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在 提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董事」）願就 本公告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所信，本公告所載資料在各重要 方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何其他事項，足以令致 本公告或其所載任何陳述產生誤導。 – 1 – （股份代號：8296） （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 中期業績 截至二零二五年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交 所上市的公司帶 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立的有限公司） （股份代號：368） 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績 公 告 德 合 集 團 控 股 有 限 公 司（「本 公 司」）董 事（「董 事」）會（「董 事 會」）欣 然 公 佈 本 公 司 及 其 附 屬 公 司（統 稱「本 集 團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 簡 明 綜 合 中 期 業 績，連 同 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 同 期 之 比 較 數 字 如 下： Superland Group Holdings Limited 德合集團控股有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 截至二零二五年六月三十日止六個月 中期業績公告 財務摘要 業績 安東油田服務集團（「本公司」）董事會（「董事會」）宣佈本公司及其附屬公司（合稱 「本集團」）截至二零二五年六月三十日止六個月（下稱「二零二五年上半年」或「報 告期內」）的未經審核簡明合併中期業績及二零二四年同期的比較數字如下： 1 • 本集團二零二五年上半年之綜合收入為人民幣約2,631.1百萬元，相比二零 二四年上半年的人民幣約2,176.3百萬元上升20.9%。 • 本集團二零二五年上半年淨利潤為人民幣約166.3百萬元，相比二零二四年 上半年的人民幣約111.6百萬元增長49.0%。 • 本集團二零二五年上半年權益持有人應佔利潤為人民幣約165.1百萬元，相 比二零二四年上半年的人民幣約105.9百萬元增長55.9%。 • 本集團二零二五年上半年經營性現金淨流入為人民幣約370.0百萬元，相比 二零二四年同期的人民幣約345.7百萬元增 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOLIMARK HOLDINGS LIMITED 映美控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2028） 未經審核綜合業績 映 美 控 股 有 限 公 司（「本 公 司」）董 事（「董 事」）會（「董 事 會」）謹 此 宣 佈，本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月（「本 期 間」）之 未 經 審 核 綜 合 業 績，連 同 二 零 二 四 年 同 期 的 比 較 數 字 如 下： 簡明綜合中期損益表 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | | --- | --- | --- | --- | --- | --- | | | | | | 未經審核 | 未經審核 | | | | | 附 註 | 人民幣千元 | 人民幣千元 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 MIDEA REAL ESTATE HOLDING LIMITED 美的置業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3990） 截 至2025年6月30日 止 六 個 月 中 期 業 績 財 務 摘 要 截 至2025年6月30日 止 六 個 月，本 集 團 持 續 經 營 業 務 營 業 收 入 為 人 民 幣 1,996.59百 萬 元，較2024年 同 期 增 長41.3%。其 中，物 管 服 務 收 入 為 人 民 幣 929.99百 萬 元，較2024年 同 期 增 長8.7%，資 產 運 營 收 入 為 人 民 幣274.93百 萬 元，較2024年 同 期 增 長13.9%，房 地 產 科 ...

Interim Results Announcement [2025 Interim Results Summary](index=1&type=section&id=2025%20Interim%20Results%20Summary) The Group reported RMB304.5 million in revenue and a RMB41.1 million loss before tax for H1 2025, driven by reduced service demand and asset impairment Key Operating Data (For the six months ended June 30) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Outpatient medical services revenue | 182,520 | 244,616 | (25.4)% | | Outpatient visits | 103,344 | 141,128 | (26.8)% | | Inpatient medical services revenue | 102,786 | 145,285 | (29.3)% | | Inpatient visits | 3,411 | 4,429 | (23.0)% | - For the six months ended June 30, 2025, revenue was **RMB304.5 million**, a decrease compared to the prior period[4](index=4&type=chunk) - For the six months ended June 30, 2025, the Group recorded a **loss before income tax of RMB41.1 million**, compared to a profit of RMB72.2 million in the prior period[4](index=4&type=chunk) - The loss was primarily due to a **RMB111.5 million decrease in revenue** from reduced demand for pediatric and obstetrics & gynecology services, along with a **goodwill impairment loss of RMB12.5 million** and an **impairment loss on property, plant and equipment of RMB21.2 million**[4](index=4&type=chunk) [Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited interim condensed consolidated financial statements for H1 2025, reflecting a shift from profit to loss and reduced asset and equity values [Interim Condensed Consolidated Statement of Comprehensive Income](index=2&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For H1 2025, the Group reported RMB304,528 thousand in revenue, an operating loss of RMB40,095 thousand, and a loss attributable to owners of RMB65,234 thousand Interim Condensed Consolidated Statement of Comprehensive Income (Summary) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Revenue | 304,528 | 415,956 | | Cost of revenue | (214,882) | (247,237) | | Impairment loss on non-current assets | (33,737) | — | | Operating (loss)/profit | (40,095) | 72,363 | | (Loss)/profit before income tax | (41,088) | 72,169 | | Income tax expense | (17,719) | (23,862) | | (Loss)/profit for the interim period | (58,807) | 48,307 | | (Loss)/profit attributable to owners of the Company | (65,234) | 25,193 | | Basic and diluted (loss)/earnings per share (RMB) | (0.14) | 0.05 | [Interim Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets decreased to RMB836,782 thousand, with equity attributable to owners at RMB478,856 thousand and total liabilities at RMB396,449 thousand Interim Condensed Consolidated Statement of Financial Position (Summary) | Indicator | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Total non-current assets | 424,203 | 478,712 | | Total current assets | 412,579 | 460,422 | | Total assets | 836,782 | 939,134 | | Equity attributable to owners of the Company | 478,856 | 553,826 | | Total equity | 440,333 | 508,876 | | Total non-current liabilities | 122,642 | 137,979 | | Total current liabilities | 273,807 | 292,279 | | Total liabilities | 396,449 | 430,258 | | Total equity and liabilities | 836,782 | 939,134 | [Notes to Interim Condensed Consolidated Financial Information](index=6&type=section&id=Notes%20to%20Interim%20Condensed%20Consolidated%20Financial%20Information) This section provides notes to the interim condensed consolidated financial information, detailing business nature, reporting basis, segment data, tax, EPS, receivables, payables, and dividends [General Information](index=6&type=section&id=General%20Information) The Group primarily offers pediatric and obstetrics & gynecology specialist services in China, including online medical services, and was listed on the HKEX in 2017 - The Group primarily provides **pediatric and obstetrics & gynecology specialist services** in China, along with online medical services[11](index=11&type=chunk) - The Company was incorporated in the Cayman Islands on July 31, 2015, and listed on the Main Board of the Hong Kong Stock Exchange on January 18, 2017[11](index=11&type=chunk)[12](index=12&type=chunk) [Basis of Preparation of Interim Report](index=6&type=section&id=Basis%20of%20Preparation%20of%20Interim%20Report) The interim condensed consolidated financial information is prepared under HKAS 34, consistent with prior year policies, and new standards are not expected to have a significant impact - The interim condensed consolidated financial information is prepared in accordance with **Hong Kong Accounting Standard 34 "Interim Financial Reporting"**[13](index=13&type=chunk) - The accounting policies adopted are consistent with the previous financial year, except for the adoption of new and revised standards, which are not expected to have a significant impact on the Group[13](index=13&type=chunk)[14](index=14&type=chunk)[15](index=15&type=chunk) [Segment Information](index=7&type=section&id=Segment%20Information) The Group's segments include pediatric, obstetrics & gynecology, and other services, with both pediatric and obstetrics & gynecology revenues decreasing in H1 2025 - The Group primarily operates three segments: **pediatric services, obstetrics & gynecology services, and other services** (including online medical services, restaurants, gift shops, etc)[16](index=16&type=chunk) Segment Revenue and Results (For the six months ended June 30) | Segment | 2025 Revenue (RMB thousands) | 2024 Revenue (RMB thousands) | 2025 Segment Results (RMB thousands) | 2024 Segment Results (RMB thousands) | | :--- | :--- | :--- | :--- | :--- | | Pediatrics | 255,693 | 360,956 | (507) | 95,127 | | Obstetrics & Gynecology | 45,312 | 51,093 | (28,636) | (15,698) | | Others | 3,523 | 3,907 | 2,883 | 546 | | Total (from external customers) | 304,528 | 415,956 | - | - | - The vast majority of revenue from external customers is recognized at a point in time, and all revenue and non-current assets primarily originate from China[19](index=19&type=chunk) [Income Tax Expense](index=8&type=section&id=Income%20Tax%20Expense) Income tax expense for H1 2025 was RMB17,719 thousand, decreasing due to the Group's loss and deferred tax asset reversal, with varying tax rates for Chinese and Hong Kong entities Income Tax Expense (For the six months ended June 30) | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Current income tax — China corporate income tax | 9,200 | 22,786 | | Deferred income tax | 8,519 | 1,076 | | Total | 17,719 | 23,862 | - Mainland China subsidiaries are subject to a **corporate income tax rate of 25%**, with high-tech enterprises enjoying a **preferential rate of 15%**[22](index=22&type=chunk) - Hong Kong profits tax rate is 16.5%, but no tax was payable during the reporting period[23](index=23&type=chunk) [Earnings Per Share](index=9&type=section&id=Earnings%20Per%20Share) For H1 2025, the loss attributable to owners resulted in a basic and diluted loss per share of **RMB0.14**, with no potential dilutive shares Earnings Per Share (For the six months ended June 30) | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | (Loss)/profit attributable to owners of the Company (RMB thousands) | (65,234) | 25,193 | | Weighted average number of ordinary shares outstanding (thousands of shares) | 483,184 | 483,184 | | Basic (loss)/earnings per share (RMB) | (0.14) | 0.05 | - For the six months ended June 30, 2025 and 2024, diluted (loss)/earnings per share were equal to basic (loss)/earnings per share, as there were no potential dilutive shares[26](index=26&type=chunk) [Trade Receivables](index=10&type=section&id=Trade%20Receivables) Net trade receivables decreased by **38.3%** to **RMB28,523 thousand** as of June 30, 2025, primarily from commercial and government insurance Trade Receivables (As of) | Item | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Trade receivables from contracts with customers | 30,219 | 47,683 | | Less: Impairment allowance for trade receivables | (1,696) | (1,533) | | Trade receivables — net | 28,523 | 46,150 | - Trade receivables primarily consist of amounts due from **commercial insurance companies and government insurance schemes**[27](index=27&type=chunk) [Trade Payables](index=11&type=section&id=Trade%20Payables) Total trade payables decreased by **24.1%** to **RMB22,653 thousand** as of June 30, 2025 Trade Payables (As of) | Ageing | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Within 3 months | 16,938 | 22,568 | | 4 to 6 months | 3,036 | 5,602 | | 7 months to 1 year | 1,281 | 458 | | Over 1 year | 1,398 | 1,288 | | Total | 22,653 | 29,916 | [Dividends](index=11&type=section&id=Dividends) For H1 2025, the Company paid a final dividend of **RMB7,996 thousand**, a decrease from the prior period, with no dividends to non-controlling shareholders Dividends Paid (For the six months ended June 30) | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Dividends paid per fully paid ordinary share during the interim period | 7,996 | 14,852 | - For the six months ended June 30, 2025, the Company paid a final dividend of **RMB7,996 thousand** (approximately HK$8,705,000)[29](index=29&type=chunk)[30](index=30&type=chunk) - For the six months ended June 30, 2025, no dividends were declared or paid to non-controlling shareholders of Beijing New Century Children's Hospital Co Ltd, a subsidiary[30](index=30&type=chunk) [Business Overview](index=12&type=section&id=Business%20Overview) The Group's H1 2025 revenue decreased by **26.8%** to **RMB304.5 million**, primarily due to reduced demand for pediatric and obstetrics & gynecology services, prompting new loyalty programs - The Group's business revenue was **RMB304.5 million**, a **26.8% year-over-year decrease**[31](index=31&type=chunk) - Pediatric services revenue was **RMB255.7 million**, a **29.2% year-over-year decrease**; obstetrics & gynecology business revenue was **RMB45.3 million**, an **11.4% year-over-year decrease**[31](index=31&type=chunk) - The significant revenue decrease was primarily due to reduced demand for pediatric and obstetrics & gynecology medical services, influenced by a decline in overall birth rates and lower incidence of internal medicine infectious diseases[32](index=32&type=chunk) - To address the decline in demand, multiple hospital campuses of the Group launched **tiered membership cards and long-term loyalty programs**[32](index=32&type=chunk) - The **loss attributable to owners of the Company was RMB65.2 million**, mainly due to declining business demand and new impairment losses on goodwill, property, plant and equipment[33](index=33&type=chunk) [Industry Outlook & Group Strategy](index=13&type=section&id=Industry%20Outlook%20%26%20Group%20Strategy) National policies and DRG/DIP reforms are shaping the healthcare industry, prompting the Group to focus on brand promotion, tiered membership, pediatric sub-specialties, and staff optimization - National policies, such as the **"Outline for Women's Development in China (2021-2030)"** and the **"Outline for Children's Development in China (2021-2030)"**, promote the development of women's and children's health, leading to significant growth in demand for comprehensive healthcare services[34](index=34&type=chunk) - **DRG/DIP payment reform** imposes higher requirements on the medical technology level of private high-end medical institutions, further highlighting their advantages and attracting individuals seeking quality services, long treatment courses, complex conditions, and mid-to-high-end commercial medical insurance[35](index=35&type=chunk) - The Group's strategy includes: **brand promotion among mid-to-high-end commercial insurance institutions**; promoting a **tiered membership card strategy** to lower renewal thresholds; focusing on **pediatric sub-specialty development** and restructuring child healthcare service product lines; and **optimizing staff structure** to enhance efficiency[37](index=37&type=chunk) [Financial Review](index=14&type=section&id=Financial%20Review) This section reviews the Group's H1 2025 financial performance, highlighting significant declines in revenue, gross profit, and gross margin, a shift to operating loss, and impacts on balance sheet items and liquidity [Segment Revenue](index=14&type=section&id=Segment%20Revenue) Medical services generated **RMB301,005 thousand** in H1 2025, representing **98.8%** of total revenue, with pediatric services contributing **84.0%** and obstetrics & gynecology **14.8%** Revenue Breakdown (For the six months ended June 30) | Item | 2025 (RMB thousands) | Proportion (%) | 2024 (RMB thousands) | Proportion (%) | | :--- | :--- | :--- | :--- | :--- | | Medical services | 301,005 | 98.8% | 412,049 | 99.1% | | Others | 3,523 | 1.2% | 3,907 | 0.9% | | Total | 304,528 | 100.0% | 415,956 | 100.0% | Composition of Pediatric and Obstetrics & Gynecology Services Revenue (For the six months ended June 30) | Service Type | 2025 (RMB thousands) | Proportion (%) | 2024 (RMB thousands) | Proportion (%) | | :--- | :--- | :--- | :--- | :--- | | Pediatric services | 255,693 | 84.0% | 360,956 | 86.8% | | Obstetrics & Gynecology services | 45,312 | 14.8% | 51,093 | 12.3% | | Total | 301,005 | 98.8% | 412,049 | 99.1% | [Cost of Revenue, Gross Profit & Gross Margin](index=15&type=section&id=Cost%20of%20Revenue%2C%20Gross%20Profit%20%26%20Gross%20Margin) For H1 2025, medical services cost of revenue decreased by **13.4%** to **RMB209.9 million**, while gross profit fell **46.9%** to **RMB89.6 million**, and gross margin declined to **29.4%** Medical Services Revenue, Cost, Gross Profit & Gross Margin (For the six months ended June 30) | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Revenue | 301,005 | 412,049 | | Cost of revenue | 209,856 | 242,370 | | Gross profit | 91,149 | 169,679 | | Gross margin | 30.3% | 41.2% | - Cost of revenue for medical services was **RMB209.9 million**, a **13.4% year-over-year decrease**[47](index=47&type=chunk) - Gross profit was **RMB89.6 million**, a **46.9% year-over-year decrease**; gross margin decreased from **40.6% to 29.4%**, primarily due to reduced demand for pediatric and obstetrics & gynecology medical services[48](index=48&type=chunk) [Operating Expenses](index=18&type=section&id=Operating%20Expenses) Selling expenses increased to **RMB33.9 million**, while administrative and R&D expenses decreased to **RMB59.1 million** and **RMB1.8 million**, respectively, alongside significant asset impairment losses - Selling expenses were **RMB33.9 million**, an **increase of 3.4% year-over-year**, primarily due to enhanced market penetration efforts[49](index=49&type=chunk) - Administrative expenses were **RMB59.1 million**, a **decrease of 2.8% year-over-year**, mainly due to cost reduction and improved operational efficiency[50](index=50&type=chunk) - Research and development expenses were **RMB1.8 million**, an **18.2% year-over-year decrease**, primarily due to reduced R&D activities[51](index=51&type=chunk) - An **impairment loss on non-current assets of RMB33.7 million** was recorded, comprising an **impairment loss on property, plant and equipment of RMB21.2 million** and a **goodwill impairment loss of RMB12.5 million**, mainly due to reduced demand for pediatric and obstetrics & gynecology services and lower-than-expected operating results[52](index=52&type=chunk) - A **net impairment loss on financial assets of RMB1.6 million** was recorded, primarily due to impairment loss on amounts due from related parties[53](index=53&type=chunk) [Financial Income and Expenses](index=19&type=section&id=Financial%20Income%20and%20Expenses) For H1 2025, finance income decreased to **RMB1.7 million** due to lower interest and exchange rate volatility, while finance costs were **RMB3.6 million**, mainly from lease interest - Finance income decreased from **RMB2.8 million to RMB1.7 million**, primarily due to lower interest income and fluctuations in exchange gains/losses[54](index=54&type=chunk) - Finance costs were **RMB3.6 million**, mainly comprising interest expenses related to lease payments[54](index=54&type=chunk) [Income Tax Expense](index=19&type=section&id=Income%20Tax%20Expense_FinancialReview) Income tax expense decreased by **25.9%** to **RMB17.7 million**, primarily due to the Group's loss and a **RMB9.0 million** deferred tax asset reversal - Income tax expense was **RMB17.7 million**, a **25.9% year-over-year decrease**[55](index=55&type=chunk) - The decrease was primarily due to the Group recording a loss and a **RMB9.0 million reversal of deferred tax assets** from wholly-owned subsidiaries[55](index=55&type=chunk) [Loss for the Period](index=19&type=section&id=Loss%20for%20the%20Period) For H1 2025, the Group reported a **loss of RMB58.8 million**, a significant shift from the **RMB48.3 million profit** in the prior period - For the six months ended June 30, 2025, the Group recorded a **loss of RMB58.8 million**, compared to a **profit of RMB48.3 million** in the prior period[56](index=56&type=chunk) [Balance Sheet Items](index=20&type=section&id=Balance%20Sheet%20Items) Inventories, trade receivables, and trade payables all decreased, reflecting a decline in medical business and reduced procurement - Inventories decreased by **16.6%** from **RMB15.7 million to RMB13.1 million**, primarily due to a decline in medical business[57](index=57&type=chunk) - Trade receivables decreased by **38.3%** from **RMB46.2 million to RMB28.5 million**, primarily due to a year-over-year decrease in medical business[58](index=58&type=chunk) - Trade payables decreased by **24.1%** from **RMB29.9 million to RMB22.7 million**, primarily due to reduced usage and procurement of pharmaceuticals and medical consumables[59](index=59&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and cash equivalents decreased by **6.4%** to **RMB331.9 million** as of June 30, 2025, with no significant investments, borrowings, or contingent liabilities, and ongoing monitoring of exchange rate risk - Cash and cash equivalents were **RMB331.9 million**, a **6.4% decrease** compared to December 31, 2024[60](index=60&type=chunk) - For the six months ended June 30, 2025, the Group had **no significant investments, acquisitions, or disposals** of subsidiaries, associates, and joint ventures[61](index=61&type=chunk)[62](index=62&type=chunk) - Capital expenditure was **RMB5.3 million**, a **34.6% year-over-year decrease**, primarily due to reduced related procurement in H1 2025[63](index=63&type=chunk) - The Group had **no borrowings** as of June 30, 2025, and December 31, 2024, thus the gearing ratio is not applicable[64](index=64&type=chunk)[70](index=70&type=chunk) - The Group primarily operates in China, with most transactions settled in RMB, and continuously monitors foreign exchange rate risks[65](index=65&type=chunk) - As of June 30, 2025, there were **no contingent liabilities, guarantees, pledges of assets, or contractual obligations** that would have a material impact on the financial position or operating results[66](index=66&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) [Employees and Remuneration Policy](index=22&type=section&id=Employees%20and%20Remuneration%20Policy) As of June 30, 2025, the Group had **1,233 employees** with total staff costs of **RMB161.1 million**, and remuneration is performance-based, including benefits and share schemes - As of June 30, 2025, the Group had **1,233 employees** (2024: 1,258 employees)[71](index=71&type=chunk) - Total staff costs were **RMB161.1 million** (2024: RMB172.2 million)[71](index=71&type=chunk) - Remuneration is determined based on employee performance, skills, qualifications, and experience, and includes social insurance, housing provident fund, performance bonuses, and discretionary bonuses[71](index=71&type=chunk) - The Group has adopted a **restricted share award scheme and an employee share scheme** to attract, retain, and supervise key employees[71](index=71&type=chunk) [Interim Dividend](index=22&type=section&id=Interim%20Dividend) The Board does not recommend an interim dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025[72](index=72&type=chunk) [Corporate Governance and Other Information](index=23&type=section&id=Corporate%20Governance%20and%20Other%20Information) The Group adheres to high corporate governance standards, complies with the Standard Code for Securities Transactions, addressed a disciplinary action, and reported no significant post-period events or listed securities transactions [Corporate Governance Code](index=23&type=section&id=Corporate%20Governance%20Code) The Company complies with the Corporate Governance Code, except for the combined Chairman and CEO roles, which the Board believes benefits the Group's strategy - The Company has complied with all applicable code provisions of the Corporate Governance Code, except for **Code Provision C.2.1** (which states that the roles of Chairman and Chief Executive Officer should be separate)[73](index=73&type=chunk) - **Mr. Jason ZHOU** serves as both Chairman and Chief Executive Officer, an arrangement the Board believes benefits the Group's business prospects, management, and overall strategic direction[73](index=73&type=chunk) [Standard Code for Securities Transactions](index=23&type=section&id=Standard%20Code%20for%20Securities%20Transactions) The Company adopted the Standard Code for directors' securities transactions, and all directors and relevant employees confirmed compliance - The Company has adopted the **Standard Code** as its code of conduct for directors' securities transactions and has established guidelines for relevant employees that are no less exacting than the Standard Code[74](index=74&type=chunk) - All directors and relevant employees have confirmed compliance with the Standard Code and the Company's guidelines for securities transactions for the six months ended June 30, 2025[74](index=74&type=chunk) [Disciplinary Action Statement](index=24&type=section&id=Disciplinary%20Action%20Statement) The Stock Exchange issued a disciplinary action statement on June 11, 2025, against the Company and directors for Listing Rule breaches, with all required training now completed - The Stock Exchange issued a **disciplinary action statement** against the Company, three executive directors, and three independent non-executive directors on **June 11, 2025**[75](index=75&type=chunk) - The Stock Exchange Listing Committee alleged that the Company violated several Listing Rules by failing to comply with announcement, circular, and/or shareholder approval requirements for providing financial assistance to connected persons[75](index=75&type=chunk) - The relevant directors breached their obligations under **Listing Rules 3.08 and 3.09B(2)** by failing to use their best endeavors to ensure the Company's compliance with internal controls and the Listing Rules[75](index=75&type=chunk) - All relevant directors have completed the training provided by a Stock Exchange-approved training institution within the stipulated timeframe[76](index=76&type=chunk) [Purchase, Sale or Redemption of Listed Securities](index=24&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Listed%20Securities) Neither the Company nor its subsidiaries purchased, sold, or redeemed any listed securities during the six months ended June 30, 2025 - For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[77](index=77&type=chunk) [Audit Committee](index=25&type=section&id=Audit%20Committee) The Audit Committee, chaired by Mr. Sun Hongbin, reviewed the Group's unaudited H1 2025 interim results, confirming their preparation according to accounting standards and adequate disclosure - The Audit Committee comprises **Mr. Sun Hongbin (Chairman)**, Mr. Jiang Yanfu (Independent Non-executive Director), and Mr. Yang Yuelin (Non-executive Director)[78](index=78&type=chunk) - The Audit Committee has reviewed the Group's unaudited interim results for the six months ended June 30, 2025, and considers them prepared in accordance with relevant accounting standards and adequately disclosed[78](index=78&type=chunk) [Post-Reporting Period Events](index=25&type=section&id=Post-Reporting%20Period%20Events) The Group reported no significant events between June 30, 2025, and the date of this announcement - The Group had no significant events between June 30, 2025, and the date of this announcement[79](index=79&type=chunk) [Publication of Interim Results Announcement and Interim Report](index=25&type=section&id=Publication%20of%20Interim%20Results%20Announcement%20and%20Interim%20Report) This interim results announcement is published on the Stock Exchange and Company websites, with the full interim report to follow for shareholders - This interim results announcement is published on the **Stock Exchange website (www.hkexnews.hk)** and the **Company's website (www.ncich.com.cn)**[80](index=80&type=chunk) - The interim report, containing all information required by the Listing Rules, will be dispatched to shareholders and published on the aforementioned websites in due course[80](index=80&type=chunk) [Definitions](index=25&type=section&id=Definitions) This section defines key terms and abbreviations used in the announcement to ensure clear understanding of the report content - This section lists definitions for key terms such as the **Board, Audit Committee, Beijing Children's Hospital, Corporate Governance Code, China, the Company, Directors, DRG/DIP payment method, Employee Share Scheme, the Group, Hong Kong, Hong Kong Financial Reporting Standards, HK$, Listing Rules, RMB, Standard Code, Remuneration Committee, Restricted Share Award Scheme, Shares, Shareholders, Stock Exchange, year-over-year, and percentage**[81](index=81&type=chunk)[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk)[88](index=88&type=chunk) [Board of Directors Information](index=27&type=section&id=Board%20of%20Directors%20Information) As of this announcement, the Board of Directors comprises executive, non-executive, and independent non-executive directors, including Mr. Jason ZHOU and Dr. Ma Jing - As of the date of this announcement, the Board of Directors comprises **three executive directors, four non-executive directors, and four independent non-executive directors**[87](index=87&type=chunk) - The executive directors are **Mr. Jason ZHOU, Ms. Xin Hong, and Mr. Xu Han**[87](index=87&type=chunk) - The independent non-executive directors are **Mr. Wu Guanxiong, Mr. Sun Hongbin, Mr. Jiang Yanfu, and Dr. Ma Jing**[87](index=87&type=chunk)